Table 4.
Parameters associated with the survival of patients
| n | Death n (%) | Median survival (months) | HR | Univariate analysis 95% CI | P | ||
|---|---|---|---|---|---|---|---|
| At diagnosis | |||||||
| WHO-FC | |||||||
| I-II | 7 | 1 (14.3) | 24 | 1 | |||
| III-IV | 34 | 3 (8.8) | 60 | 0.513 | 0.053 - 4.955 | 0.564 | |
| Treatment | |||||||
| Monotherapy | 23 | 2 (8.7) | 60 | 1 | |||
| Combination therapy | 18 | 2 (11.2) | 60 | 1.327 | 0.187 - 9.428 | 0.777 | |
| mPAP | 41 | 4 (9.8) | 60 | 1.010 | 0.960 - 1.063 | 0.694 | |
| PVRi | 41 | 4 (9.8) | 60 | 1.050 | 0.992 - 1.110 | 0.091 | |
| Rp/Rs | 41 | 4 (9.8) | 60 | 0.696 | 0.059 - 8.194 | 0.773 | |
| 6MWT | 41 | 4 (9.8) | 60 | 0.990 | 0.979 - 1.001 | 0.080 | |
| ProBNP | 41 | 4 (9.8) | 60 | 1.001 | 1.000 - 1.001 | 0.004 | |
| Uric acid | 41 | 4 (9.8) | 60 | 1.404 | 0.794 - 2.481 | 0.243 | |
| At last evaluation | |||||||
| WHO-FC | |||||||
| I-II | 32 | 1 (3.1) | 60 | 1 | |||
| III-IV | 9 | 3 (33.3) | 60 | 9.393 | 0.975 - 90.492 | 0.053 | |
| 6MWT | 41 | 4 (9.8) | 60 | 0.984 | 0.969 - 0.998 | 0.027 | |
| ProBNP | 41 | 4 (9.8) | 60 | 1.001 | 1.000 - 1.001 | 0.001 | |
| Uric acid | 41 | 4 (9.8) | 60 | 1.525 | 1.045 - 2.227 | 0.029 |
6MWT - 6-min walk test; proBNP - pro-brain natriuretic peptide; WHO-FC - WHO functional class; mPAP - mean pulmonary artery pressure; PVRi - pulmonary vascular resistance index; Rp/Rs - pulmonary resistance/systemic resistance; Qp/Qs - pulmonary flow/systemic flow